---
title: 'Scientist II, In-Vitro & Nonclinical Assay Development at Tonix Pharmaceuticals'
canonical: 'https://feeny.ai/job/scientist-ii-in-vitro-nonclinical-assay-development-tonix-pharmaceuticals-xfw3p1cqhsr3'
type: 'job'
last_seen: '2026-09-09'
---

# Scientist II, In-Vitro & Nonclinical Assay Development at Tonix Pharmaceuticals 

- **Company:** Tonix Pharmaceuticals 
- **Location:** Frederick, MD
- **Compensation:** $100k–$140k
- **Posted:** 2026-08-21
- **Last confirmed live:** 2026-09-09
- **Apply:** https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4378888009

## Job description

Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti-Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit [www.tonixpharma.com](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D9p5FBvlzG2u-9NzVEDdUgRNdl57Mw08p4h9XviYYnbwVJ-X_DNEOeN4RdGA64IhTnk9R4lQWNXhq0g8TrvoRTCZSpqmowBapMZCbqP_sxm0%3D&data=05%7C02%7Cmarsha.ihrig%40tonixpharma.com%7C016ba434378242bb501908dea48d8908%7C9f3c9f8851ca4393815e405a5f206a29%7C0%7C0%7C639129124987080441%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=WrmW8ZuY9XRYJZM0BMPu3thoab5uVHnt9SqBNHIoDuU%3D&reserved=0) and follow the Company on [LinkedIn](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DbldblPUeLBo2VtrimIDsthVk4RaPH1sCjnDw18J2Q9UGKOYpi7kKsd6NuJ4rb7a1ocGevguAt4l_8t8TE5rfCP1YmSBTJO1HR9Uo9KAv_DEwtbEkJhm1CdLRAEbAUNB-&data=05%7C02%7Cmarsha.ihrig%40tonixpharma.com%7C016ba434378242bb501908dea48d8908%7C9f3c9f8851ca4393815e405a5f206a29%7C0%7C0%7C639129124987109283%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=dHRzyv5dfKFOhCroh809txjNcJOjNrBSQRyfSgHaIu8%3D&reserved=0) and [X](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D0NgIEJjy96AytWlfgCqgqVv5cOeUVkGOTFS78koSy22XXOczOtXjxSorNUcN-uDTk4CYVQkJndgCk6o2RQBlKQ%3D%3D&data=05%7C02%7Cmarsha.ihrig%40tonixpharma.com%7C016ba434378242bb501908dea48d8908%7C9f3c9f8851ca4393815e405a5f206a29%7C0%7C0%7C639129124987130654%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=frLcoK5ETOWzJq9lmvkirCS8HaHc2WCX%2Fg4ESMSdLgk%3D&reserved=0).

*Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

Job Summary

Scientist II will support Tonix Pharmaceuticals’ preclinical research programs through the development, optimization, and execution of in vitro and nonclinical assays. The role will contribute to translational research using cell-based assays, DMPK/ADME assays, 3D cell culture and organoid systems, and other nonclinical models to evaluate therapeutic candidates. The scientist will work collaboratively across discovery and development programs and generate high-quality, reproducible data to support program decisions.

Essential Functions

- Develop, optimize, and execute in vitro cell-based and biochemical assays to support drug discovery and preclinical development programs.
- Perform and support DMPK/ADME assays, including permeability, protein binding, metabolic or CYP-related assays, cytotoxicity, and other screening assays as appropriate.
- Develop and evaluate 3D cell culture, spheroid, and organoid-based assay systems for translational and nonclinical studies.
- Support the development and execution of nonclinical assays and models for evaluation of therapeutic efficacy, pharmacology, safety, and mechanism of action.
- Design experiments, develop and optimize protocols, analyze data, troubleshoot assays, and document results in laboratory records and technical reports.
- Maintain mammalian cell culture systems, including established cell lines and primary or specialized cell systems as needed for project-specific assays.
- Apply molecular, biochemical, imaging, and viability-based assay methods, including techniques such as RT-PCR, Western blotting, ELISA, luminescence-based assays, microscopy, and related analytical readouts.
- Work collaboratively with internal scientists and external partners/CROs to support preclinical and DMPK studies.
- Prepare data summaries, presentations, protocols, reports, and other documentation supporting research programs and regulatory or development activities.
- Maintain accurate records and perform work in accordance with applicable laboratory, quality, and safety procedures.

Necessary Skills and Abilities

- Strong hands-on experience with mammalian cell culture and in vitro assay development.
- Experience designing, optimizing, troubleshooting, and interpreting cell-based, biochemical, or translational assays.
- Familiarity with DMPK/ADME assay concepts and laboratory methods is preferred.
- Experience with 3D culture systems, spheroids, organoids, or other advanced in vitro models is preferred.
- Experience supporting nonclinical or preclinical drug development studies.
- Proficiency with common molecular and biochemical laboratory techniques and quantitative data analysis.
- Strong experimental planning, problem-solving, technical writing, presentation, and communication skills.
- Ability to work independently while collaborating effectively in multidisciplinary project teams.

Educational Requirements

- Ph.D. in Pharmacology, Biochemistry, Biology, Biotechnology, Pharmaceutical Sciences, or a related life sciences discipline; with 2+ years of relevant experience or an M.S. with 4+ years of relevant research experience.

## Experience Requirements

- Relevant hands-on research experience in pharmaceutical, biotechnology, CRO, government, or academic research environments.
- Experience with in vitro pharmacology, assay development, DMPK/ADME, 3D culture/organoid models, or nonclinical research is preferred.
- Experience generating reproducible experimental data and communicating results to multidisciplinary teams. Salary Range $100,000—$140,000 USD

*Please note that Tonix does not offer sponsorship for this role.

Recruitment & Staffing Agencies

Tonix does not accept agency resumes unless contacted directly by internal Tonix Talent Acquisition. Please do not forward resumes to Tonix employees or any other company location; Tonix is not responsible for any fees related to unsolicited resumes.

## Compensation & Benefits

Tonix provides a comprehensive compensation and benefits package which includes:

- Medical, Dental & Vision Insurance, Basic and Voluntary Life and AD&D Insurance, Short- and Long-Term Disability Insurance, Flexible Spending Accounts, Health Savings Account, and Employee Assistance Programs
- Pet Insurance
- Retirement Savings 401k with company match and annual discretionary stock options
- Generous Paid Time Off, Sick Time, & Paid Holidays
- Career Development and Training

Tonix provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, sex, national origin, age, genetics, or any other characteristic protected by law.  In addition to federal law requirements, Tonix complies with applicable state and local laws governing nondiscrimination in employment.  This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfers, leaves of absence, compensation, and training.  Tonix expressly prohibits any form of workplace harassment based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin, age, genetic, information, disability, veteran status, or any other characteristic protected by law.

## About Tonix Pharmaceuticals 

## Company Overview
- **One-liner**: A fully-integrated biopharmaceutical company commercializing and developing innovative therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases.
- **Entity Type**: Public (NASDAQ: TNXP)
- **Headquarters**: Berkeley Heights, New Jersey, United States (as indicated by zip code 07922 on the investor relations page) [ir.tonixpharma.com](https://ir.tonixpharma.com/)
- **Founded**: Not publicly available from provided sources
- **Founders**: Not publicly available from provided sources

## Core Business
- **Primary industry/industries**: Biotechnology / Pharmaceuticals (therapeutics)
- **Target customers**: B2B – physicians (rheumatology, primary care, pain management, neurology), hospitals, specialty distributors, and patients through prescription-based access.
- **Mission or purpose statement**: “We listen, we develop, we deliver – so that patients feel seen, heard, and empowered to live fully again.” [tonixpharma.com](https://www.tonixpharma.com/)

## Products & Services
- **TONMYA® (cyclobenzaprine HCl sublingual tablets)**: Approved in the U.S. (August 2025) and launched in November 2025 for the treatment of fibromyalgia in adults – the first new medicine for fibromyalgia in over 15 years. Non-opioid, centrally acting analgesic designed for bedtime dosing. [tonixpharma.com](https://www.tonixpharma.com/)
- **Zembrace® SymTouch® (sumatriptan injection)**: FDA-approved prescription product for the treatment of acute migraine. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **Tosymra® (sumatriptan nasal spray)**: FDA-approved prescription product for acute migraine. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **TNX-102 SL (cyclobenzaprine HCl sublingual tablets)**: Investigational for Major Depressive Disorder (Phase 2 planned mid-2026) and Acute Stress Disorder/Reaction (Phase 2 enrolling, OASIS study at UNC funded by DoD). [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **TNX-4800 (anti-OspA monoclonal antibody)**: Seasonal prevention of Lyme disease – Phase 2 field study planned first half 2027. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **TNX-1500 (humanized anti-CD40L mAb)**: Phase 2-ready for prevention of kidney transplant rejection (investigator-initiated study expected mid-2026) and treatment of autoimmune diseases. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **TNX-1300 (double-mutant cocaine esterase)**: Phase 2 for cocaine intoxication; FDA Breakthrough Therapy designation. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **TNX-2900 (intranasal oxytocin + magnesium)**: For Prader-Willi Syndrome – Orphan Drug and Rare Pediatric Disease designations; Phase 2 planned Q1 2027. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **TNX-801 (horsepox live virus vaccine)**: Preclinical – mpox/smallpox protection; Phase 1 expected in 2027. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **TNX-4200 (small molecule anti-CD45)**: Broad-spectrum antiviral for biodefense; preclinical, supported by up to $34M DoD contract. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **TNX-1700 (TFF2-albumin fusion)**: Preclinical for gastric/colorectal cancer in combination with PD-1 blockade (in-licensed from Columbia University). [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)
- **TNX-4900 (Sigma-1 receptor antagonist)**: Preclinical non-opioid analgesic for neuropathic pain. [10-K](https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-26-005730/0001999371-26-005730.pdf)

## Market Standing
- **Valuation/Market Cap**: Not publicly available from provided sources (public stock; market cap fluctuates)
- **Key Metric**: Annual Revenue – Not disclosed in provided sources (commercial launch of TONMYA began November 2025; earlier revenue from Zembrace/Tosymra). Total funding rounds not applicable for public company. R&D expenditures detailed in 10-K but not extracted.
- **Notable Investors/Partners**: Almac Pharma Services (commercial supply for TONMYA) [10-K]; U.S. Department of Defense (DTRA contract up to $34M for TNX-4200) [10-K]; University of North Carolina (OASIS study for TNX-102 SL) [10-K]; Columbia University (TNX-1700 in-license) [10-K].
- **Growth Signals**: First FDA approval and launch of internally developed drug TONMYA (Nov 2025); expanding commercial payer coverage (second commercial agreement covering ~52M U.S. lives) [tonixpharma.com]; multiple Phase 2 programs advancing; ownership of two manufacturing facilities (RDC in Frederick, MD and ADC in Dartmouth, MA) [10-K].

## Competitive Advantages
- **First-mover in fibromyalgia**: TONMYA is the first new FDA-approved treatment for fibromyalgia in 15+ years, with a proprietary sublingual formulation that offers differentiated bioavailability and tolerability.
- **Broad, diversified pipeline**: Covers CNS, immunology, infectious disease, and rare disease – reducing single-program risk and providing multiple shots on goal.
- **In-house manufacturing**: Owned R&D Center (Frederick, MD) with BSL-2/3 capability and an Advanced Development Center (Dartmouth, MA) for live-virus vaccine and biologics production (currently decommissioned but ready for reactivation) [10-K].
- **Non-opioid focus**: All analgesic candidates (TONMYA, TNX-4900) are non-opioid, aligning with regulatory and societal trends away from opioids.
- **Government partnerships**: DTRA contract for biodefense work (TNX-4200) provides non-dilutive funding and mission relevance.

## Strategic Focus
- **Grow TONMYA**: Expand commercial coverage, physician adoption, and patient access for fibromyalgia treatment.
- **Advance pipeline**: Initiate or complete Phase 2 studies for TNX-102 SL (MDD, ASD), TNX-4800 (Lyme), TNX-1500 (transplant rejection), TNX-1300 (cocaine intoxication), TNX-2900 (Prader-Willi), and move TNX-801 (mpox/smallpox vaccine) into Phase 1.
- **Pursue strategic business development**: In-licensing, partnerships, and potential acquisitions to augment pipeline and commercial portfolio [10-K].

## Why Work Here
- **Culture**: The company emphasizes a collaborative, inclusive environment where every voice is heard. Mission-driven focus on “listening to patients’ lived experiences” and developing therapies for underserved, complex conditions. [tonixpharma.com/careers](https://www.tonixpharma.com/careers/)
- **Work model**: Information on remote/hybrid policy not publicly available. Office and lab facilities in Berkeley Heights, NJ (HQ), Frederick, MD (R&D Center), and Dartmouth, MA (Advanced Development Center).
- **Team & growth**: Opportunity to work on first-in-class drug launches (TONMYA) and cutting-edge science across multiple therapeutic areas. The company is at a pivotal stage transitioning from pure R&D to a commercial organization, offering varied career pathways.
- **Benefits**: Equal opportunity employer; does not offer visa sponsorship for open positions. [tonixpharma.com/careers](https://www.tonixpharma.com/careers/)
- **Notable perks/engineering culture**: Not detailed, but the science-driven environment with in-house manufacturing and government-funded biodefense work may appeal to researchers and engineers in pharma.

## Sources
1. [tonixpharma.com](https://www.tonixpharma.com/) – Company homepage, mission, product info, lat

_…truncated._

## Other roles at Tonix Pharmaceuticals 

- [Executive Assistant to the Chief Executive Officer](https://feeny.ai/job/executive-assistant-to-the-chief-executive-officer-tonix-pharmaceuticals-q21ne61fzfhr) — Berkeley Heights NJ OR New York, NY
- [Regional Sales Director - California](https://feeny.ai/job/regional-sales-director-california-tonix-pharmaceuticals-california-8thn8v1c8d4r) — California
- [Associate Medical Director, Clinical Development](https://feeny.ai/job/associate-medical-director-clinical-development-tonix-pharmaceuticals-berkeley-pa6mx85qwvws) — Berkeley Heights, NJ
- [Manager, Financial Reporting](https://feeny.ai/job/manager-financial-reporting-tonix-pharmaceuticals-berkeley-heights-x4szc7r8yxkq) — Berkeley Heights, NJ
- [Senior Associate, Supplier Quality](https://feeny.ai/job/senior-associate-supplier-quality-tonix-pharmaceuticals-north-dartmouth-ma-or-bfw25b7mxm0z) — North Dartmouth MA OR Berkeley Height, NJ
- [Senior Manager, Information Security](https://feeny.ai/job/senior-manager-information-security-tonix-pharmaceuticals-frederick-md-or-062sk1rtyd2t) — Frederick MD OR Berkeley Heights, NJ
- [​Pharmaceutical Management Rotational Program Associate​](https://feeny.ai/job/pharmaceutical-management-rotational-program-associate-tonix-pharmaceuticals-y27n7mcn4xq0) — Berkeley Heights, NJ
- [Senior Specialist, Corporate Communications](https://feeny.ai/job/senior-specialist-corporate-communications-tonix-pharmaceuticals-berkeley-0rn9ax1k9r08) — Berkeley Heights NJ OR New York, NY
- [Associate Director, Commercial Analytics & Sales Force Effectiveness](https://feeny.ai/job/associate-director-commercial-analytics-sales-force-effectiveness-tonix-21gmwfrwft16) — Berkeley Heights, NJ
- [Senior Manager, Congress Planning & Management](https://feeny.ai/job/senior-manager-congress-planning-management-tonix-pharmaceuticals-berkeley-2r5mphhs7zk2) — Berkeley Heights, NJ